ArticleJournal of cancer research and clinical oncology2022

Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.

Yung-Hung Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.